<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031785</url>
  </required_header>
  <id_info>
    <org_study_id>REBACDR0000069226</org_study_id>
    <secondary_id>CCCWFU-98199</secondary_id>
    <secondary_id>NCI-P02-0210</secondary_id>
    <nct_id>NCT00031785</nct_id>
  </id_info>
  <brief_title>Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized Study of the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer Patients Receiving Thoracic Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in&#xD;
      limiting weight loss in patients who are undergoing radiation therapy.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in limiting&#xD;
      weight loss in patients who are undergoing radiation therapy for lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effect of megestrol on weight in patients receiving radiotherapy for lung&#xD;
           cancer.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients&#xD;
      are stratified according to histology (non-small cell lung cancer vs small cell lung cancer),&#xD;
      and type of treatment (radiotherapy vs radiotherapy and non-cisplatin-containing chemotherapy&#xD;
      vs radiotherapy and cisplatin-containing chemotherapy). Patients are randomized to one of two&#xD;
      treatment arms.&#xD;
&#xD;
      All patients undergo thoracic radiotherapy beginning on week 1 and continuing for a total of&#xD;
      5-7 weeks.&#xD;
&#xD;
        -  Arm I: Patients receive oral megestrol once daily beginning within the first 3 days of&#xD;
           radiotherapy and continuing until 12 weeks after the completion of radiotherapy.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily beginning within the first 3 days of&#xD;
           radiotherapy and continuing until 12 weeks after the completion of radiotherapy.&#xD;
&#xD;
      In both arms, quality of life is assessed at baseline, at the completion of radiotherapy, and&#xD;
      at 4, 8, 12, 16, and 20 weeks after the completion of radiotherapy.&#xD;
&#xD;
      Patients are followed at 4 and 8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 98 patients (49 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2000</start_date>
  <completion_date type="Actual">September 11, 2002</completion_date>
  <primary_completion_date type="Actual">September 11, 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">25</enrollment>
  <condition>Anorexia</condition>
  <condition>Cachexia</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>megestrol acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed lung cancer&#xD;
&#xD;
               -  Unresectable stage I-IIIB non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Resected stage I-IIIB NSCLC&#xD;
&#xD;
               -  Limited stage small cell lung cancer&#xD;
&#xD;
          -  Planned radiotherapy with a total dose of at least 5,000 cGy in fraction sizes of no&#xD;
             greater than 200 cGy each&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  No significant ascites, pleural effusions, or edema that would inhibit oral food&#xD;
             intake or invalidate weight determinations&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No active thromboembolic disease&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No prior congestive heart failure or thromboembolic events&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No prior pulmonary edema&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 3 years except curatively treated carcinoma in&#xD;
             situ of the cervix or non-melanoma skin cancer&#xD;
&#xD;
          -  No uncontrolled diabetes with glycosylated hemoglobin greater than 10%&#xD;
&#xD;
          -  No Cushing's syndrome&#xD;
&#xD;
          -  No dietary restrictions (e.g., salt, sugar, or lipid)&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Endocrine therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 12 months since prior corticosteroids, estrogens, progestins, or other&#xD;
             steroid hormone except as antiemetic prior to chemotherapy&#xD;
&#xD;
          -  No concurrent corticosteroids, estrogens, progestins, or other steroid hormone except&#xD;
             as antiemetic prior to chemotherapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to lung&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 14 days since prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward G. Shaw, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>August 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2003</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>anorexia</keyword>
  <keyword>cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

